Delving into the Latest Updates on RV-1729 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

RV 1729

Target

PI3Kγ x PI3Kδ

Action

inhibitors

Mechanism

PI3Kγ inhibitors(Phosphatidylinositol 3 kinase gamma inhibitors), PI3Kδ inhibitors(Phosphatidylinositol 3 kinase delta inhibitors)

Therapeutic Areas

Immune System DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

AsthmaPulmonary Disease, Chronic Obstructive

Originator Organization

RespiVert Ltd.

Active Organization-

Inactive Organization

RespiVert Ltd.

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC39H39ClN8O5

InChIKeyUBLOHCIYTDRGJH-UHFFFAOYSA-N

CAS Registry1293915-42-0

RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD). The objective of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics repeat doses of RV1729 in patients with COPD for 28 days.

Start Date01 Aug 2014

Sponsor / Collaborator

RespiVert Ltd.

NCT02140320

/ CompletedPhase 1

A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV1729 in Healthy Subjects for up to 28 Days and Subjects With Stable Asthma for 14 Days

RV1729 is a new medicine being developed for the potential treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
The objective of this study is to investigate the safety, tolerability and pharmacokinetics of single doses of RV1729 and repeat doses of RV1729 for up to 28 days.

Start Date01 Jul 2014

Sponsor / Collaborator

RespiVert Ltd.

NCT01813084

/ CompletedPhase 1

A Randomised, Double Blind, Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV1729 in Healthy Subjects and Subjects With Mild to Moderate Asthma

RV1729 is a new medicine being developed for possible treatment of asthma and smoking related lung disease (also known as chronic obstructive pulmonary disease - COPD).
The main purpose of this study is to investigate the safety, tolerability and pharmacokinetics of single and repeat doses of RV1729.

Start Date01 May 2013

Sponsor / Collaborator

RespiVert Ltd.

100 Clinical Results associated with RV-1729

Login to view more data

100 Translational Medicine associated with RV-1729

Login to view more data

100 Patents (Medical) associated with RV-1729

Login to view more data

2

Literatures (Medical) associated with RV-1729

13 Feb 2025·JOURNAL OF MEDICINAL CHEMISTRY

How to Design an Inhaled Drug: CHF-6523

Article

Author: Perry, Matthew W. D.

Inhalation provides an opportunity to target drugs to the lung, potentially improving efficacy and safety margins for the treatment of respiratory conditions. The discovery of inhaled medicines is a specialized endeavor and has different challenges to medicinal chemistry for oral drugs. The appearance of a successful campaign delivering an inhaled PI3Kδ inhibitor is therefore an opportunity to highlight how a team can address the challenges involved in the identification of such a compound. This Viewpoint seeks to highlight a great example of medicinal chemistry in the inhaled space.

01 Apr 2014·Expert opinion on therapeutic patentsQ2 · MEDICINE

Evaluation of WO2013136076: two crystalline forms of the phosphatidylinositol 3-kinase-δ inhibitor RV-1729

Q2 · MEDICINE

Article

Author: Norman, Peter

This application claims two crystalline forms and inhaled formulations of a the selective phosphatidylinositol 3-kinase-δ inhibitor (PI3Kδ) inhibitor 6-(2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(2-chlorobenzyl)-4-oxo-3,4-dihydroquinazolin-5-yl)-N, N-bis(2-methoxyethyl)hex-5-ynamide. These formulations are claimed to be useful in the treatment of respiratory diseases including asthma and chronic obstructive pulmonary disease.

100 Deals associated with RV-1729

Login to view more data